FDA grants RMAT status to Editas Medicine’s sickle cell disease therapy
EDIT-301 is an investigational, gene editing medicine which consists of patient derived CD34+ hematopoietic stem and progenitor cells…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Oct 23
EDIT-301 is an investigational, gene editing medicine which consists of patient derived CD34+ hematopoietic stem and progenitor cells…
17 Oct 23
New agreement to establish global commercial manufacturing capacity for Vaxcyte's PCV candidates, VAX-24 and VAX-31, in adult and…
17 Oct 23
The med-tech supply sector shows off its “high-performance mode”
17 Oct 23
AspyreRx is the first FDA-authorized digital behavioral therapeutic device delivering cognitive behavioral therapy for the treatment of a…
16 Oct 23
Velsipity is an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator, approved by the US FDA to treat moderately…
16 Oct 23
Skyrizi is an interleukin-23 inhibitor that selectively blocks IL-23, a cytokine involved in inflammatory processes and is associated…
16 Oct 23
The designation was given based on positive data from the Phase 1 part of the ongoing Phase 1/2…
16 Oct 23
NewChem Technologies is a contract services provider and supplies customers in pharmaceuticals, diagnostics and biotechnology to veterinary science…
16 Oct 23
ORi to Be Launched in the U.S. at ANESTHESIOLOGY 2023 This Weekend
16 Oct 23
bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS® TBI (GFAP, UCH-L1), a blood…